...
首页> 外文期刊>The oncologist >Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Resultsa??Medicare Analysis
【24h】

Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Resultsa??Medicare Analysis

机译:评估老年胰腺癌患者的治疗方式和生存结果:监测,流行病学和最终结果a ??医疗保险分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background. Management of pancreatic cancer (PC) in elderly patients is unknown; clinical trials exclude patients with comorbidities and those of extreme age. This study evaluated treatment patterns and survival outcomes in elderly PC patients using linked Surveillance, Epidemiology, and End Results (SEER) and Medicare data. Materials and Methods. Histology codes 8140, 8500, 8010, 8560, 8490, 8000, 8260, 8255, 8261, 8263, 8020, 8050, 8141, 8144, 8210, 8211, or 8262 in Medicare Parts A and B were identified. Data regarding demographic, characteristics, treatments, and vital status between 1998 and 2009 were collected from the SEER. Determinants of treatment receipt and overall survival were examined using logistic regression and Cox proportional hazards models, respectively. Results. A total of 5,975 patients met inclusion. The majority of patients were nona??Hispanic whites (85%) and female (55%). Most cases presented with locoregional stage disease (74%); 41% received only chemotherapy, 30% chemotherapy and surgery, 10% surgery alone, 3% radiation, and 16% no cancera??directed therapy. Patients with more advanced cancer, older age, and those residing in areas of poverty were more likely to receive no treatment. Among patients 66a??74 years of age with locoregional disease, surgery alone (hazard ratio [HR]a??=a??0.54; 95% confidence interval [CI]: 0.39a??0.74) and surgery in combination with chemotherapy (HRa??=a??0.69; 95% CI: 0.53a??0.91) showed survival benefit as compared with the no treatment group. Among patients a?¥75 years of age with locoregional disease, surgery alone (HRa??=a??2.04; 95% CI: 0.87a??4.8) or in combination with chemotherapy (HRa??=a??1.59; 95% CI: 0.87a??2.91) was not associated with better survival. Conclusion. Treatment modality and survival differs by age and stage. Low socioeconomic status appears to be a major barrier to the receipt of PC therapy among Medicare patients. Implications for Practice. Elderly patients with cancer are undera??represented on clinical trials and usually have comorbid illnesses. The management of elderly patients with pancreatic cancer is unknown, with many retrospective experiences but low sample sizes. Using Surveillance, Epidemiology, and End Resultsa??Medicare linked data to analyze treatment patterns and survival of elderly patients with pancreatic cancer on a larger population scale, this study highlights treatment patterns and their effect on survival and proposes possible obstacles to access of care in elderly patients with pancreatic cancer other than Medicare coverage.
机译:背景。老年患者的胰腺癌(PC)的管理尚不清楚;临床试验排除了合并症和极端年龄的患者。这项研究使用相关的监测,流行病学,最终结果(SEER)和Medicare数据评估了老年PC患者的治疗方式和生存结果。材料和方法。在Medicare部件A和B中识别出组织学代码8140、8500、8010、8560、8490、8000、8260、8255、8261、8263、8020、8050、8141、8144、8210、8211或8262。从SEER中收集了1998年至2009年之间有关人口统计,特征,治疗和生活状况的数据。分别使用logistic回归和Cox比例风险模型检查了治疗接受度和总生存率的决定因素。结果。共有5,975例患者入选。多数患者为非诺拉美裔西班牙裔白人(85%)和女性(55%)。大多数病例表现为局部区域疾病(74%); 41%仅接受化学疗法,30%接受化学疗法和手术,仅10%接受手术,3%放射治疗和16%没有接受癌症定向治疗。癌症晚期,高龄患者以及生活在贫困地区的患者更有可能不接受治疗。在患有局部区域性疾病的66a ?? 74岁患者中,单独进行手术(危险比[HR] a ?? = a ?? 0.54; 95%置信区间[CI]:0.39a ?? 0.74)和联合化疗的手术与未治疗组相比,HRa(α3+ = a-α0.69; 95%CI:0.53a-0.91)显示出生存益处。年龄≥75岁的局部疾病患者中,仅接受手术治疗(HRa25 = a ?? 2.04; 95%CI:0.87a ?? 4.8)或联合化疗(HRa25 = a ?? 1.59; 95%CI:0.87a≤2.91)与更好的生存率无关。结论。治疗方式和生存率因年龄和阶段而异。社会经济地位低下似乎是Medicare患者接受PC疗法的主要障碍。对实践的启示。老年癌症患者临床研究不足,通常患有合并症。老年胰腺癌患者的治疗尚不明确,具有许多回顾性经验,但样本量较小。通过使用监测,流行病学和最终结果a?Medicare链接数据来分析较大规模的老年胰腺癌患者的治疗模式和生存率,本研究重点介绍了治疗模式及其对生存率的影响,并提出了可能获得医疗服务的障碍老年胰腺癌患者(医疗保险除外)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号